Francesca Pavone
IRBM Science Park · 23 works · 190 citations · h-index 10
Top works
- Synthesis and Pharmacological Characterization of Novel Druglike Corticotropin-Releasing Factor 1 Antagonists
- Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders
- Substituted tetraazaacenaphthylenes as potent CRF1 receptor antagonists for the treatment of depression and anxiety
- Novel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists
- Novel carbazole derivatives as NPY Y1 antagonists
- Cyclopenta[d]pyrimidines and Dihydropyrrolo[2,3‐d]pyrimidines as Potent and Selective Corticotropin‐Releasing Factor 1 Receptor Antagonists
- Novel Spirotetracyclic Zwitterionic Dual H1/5-HT2AReceptor Antagonists for the Treatment of Sleep Disorders
- Discovery Process and Characterization of Novel Carbohydrazide Derivatives as Potent and Selective GHSR1a Antagonists
- SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease
- Heteroaryl‐Substituted 4‐(1H‐pyrazol‐1‐yl)‐5,6‐dihydro‐1H‐pyrrolo[2,3‐d]pyrimidine Derivatives as Potent and Selective Corticotropin‐Releasing Factor Receptor‐1 Antagonists
- Asymmetric route to spirotetracyclic (1S)-5′,11′-dihydro-3H-spiro[cyclopentane-1,10′-dibenzo[a,d]cyclohepten]-3-one derivatives
- UN CASO DI MALATTIA SIMIL-CELIACA DA MYCOPLASMA PNEUMONIAE
- II bambino asmatico e lo sport: Revisione della letteratura ed esperienza personale
- Ricerche virologiche ed osservazioni cliniche in affezioni respiratorie acute dell'infanzia nel corso di un eoidemia
- Alcune valutazioni etiopatogenetiche della sindrome orticaria angioedema
- ChemInform Abstract: Novel Imidazobenzazepine Derivatives as Dual H1/5‐HT2A Antagonists for the Treatment of Sleep Disorders.
- La sindrome emolitica uremica: contributo casistico
- Il bambino asmatico e lo sport
- [Calcium-heparin treatment of chronic disseminated intravascular coagulation in liver cirrhosis].
- Significato predittivo del FEF 25%-75% nel bambino asmatico